- Home
- NCL vs UBX Comparison
NCL vs UBX Comparison
Compare NCL & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCL
- UBX
- Stock Information
- Founded
- NCL 2013
- UBX 2009
- Country
- NCL United States
- UBX United States
- Employees
- NCL N/A
- UBX N/A
- Industry
- NCL
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- NCL
- UBX Health Care
- Exchange
- NCL Nasdaq
- UBX Nasdaq
- Market Cap
- NCL 21.7M
- UBX 12.7M
- IPO Year
- NCL 2023
- UBX 2018
- Fundamental
- Price
- NCL $0.95
- UBX $0.72
- Analyst Decision
- NCL
- UBX Strong Buy
- Analyst Count
- NCL 0
- UBX 3
- Target Price
- NCL N/A
- UBX $4.67
- AVG Volume (30 Days)
- NCL 7.7M
- UBX 195.7K
- Earning Date
- NCL 06-10-2025
- UBX 04-22-2025
- Dividend Yield
- NCL N/A
- UBX N/A
- EPS Growth
- NCL N/A
- UBX N/A
- EPS
- NCL N/A
- UBX N/A
- Revenue
- NCL $15,576,857.00
- UBX N/A
- Revenue This Year
- NCL N/A
- UBX N/A
- Revenue Next Year
- NCL N/A
- UBX N/A
- P/E Ratio
- NCL N/A
- UBX N/A
- Revenue Growth
- NCL 47.13
- UBX N/A
- 52 Week Low
- NCL $0.15
- UBX $0.66
- 52 Week High
- NCL $1.03
- UBX $3.10
- Technical
- Relative Strength Index (RSI)
- NCL 73.85
- UBX 35.48
- Support Level
- NCL $0.77
- UBX $0.66
- Resistance Level
- NCL $0.97
- UBX $0.81
- Average True Range (ATR)
- NCL 0.16
- UBX 0.08
- MACD
- NCL 0.02
- UBX 0.00
- Stochastic Oscillator
- NCL 87.14
- UBX 21.49
About NCL Northann Corp.
Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.